472 related articles for article (PubMed ID: 27974723)
21. Editing the Epigenome to Tackle Brain Disorders.
Liu XS; Jaenisch R
Trends Neurosci; 2019 Dec; 42(12):861-870. PubMed ID: 31706628
[TBL] [Abstract][Full Text] [Related]
22. Technologies and Computational Analysis Strategies for CRISPR Applications.
Clement K; Hsu JY; Canver MC; Joung JK; Pinello L
Mol Cell; 2020 Jul; 79(1):11-29. PubMed ID: 32619467
[TBL] [Abstract][Full Text] [Related]
23. Editing the epigenome: technologies for programmable transcription and epigenetic modulation.
Thakore PI; Black JB; Hilton IB; Gersbach CA
Nat Methods; 2016 Feb; 13(2):127-37. PubMed ID: 26820547
[TBL] [Abstract][Full Text] [Related]
24. CRISPR-Cas System: The Current and Emerging Translational Landscape.
Bhokisham N; Laudermilch E; Traeger LL; Bonilla TD; Ruiz-Estevez M; Becker JR
Cells; 2023 Apr; 12(8):. PubMed ID: 37190012
[TBL] [Abstract][Full Text] [Related]
25. PIWI-Interacting RNA (piRNA) and Epigenetic Editing in Environmental Health Sciences.
Perera BPU; Morgan RK; Polemi KM; Sala-Hamrick KE; Svoboda LK; Dolinoy DC
Curr Environ Health Rep; 2022 Dec; 9(4):650-660. PubMed ID: 35917009
[TBL] [Abstract][Full Text] [Related]
26. Epigenome Editing: State of the Art, Concepts, and Perspectives.
Kungulovski G; Jeltsch A
Trends Genet; 2016 Feb; 32(2):101-113. PubMed ID: 26732754
[TBL] [Abstract][Full Text] [Related]
27. CRISPR: From Prokaryotic Immune Systems to Plant Genome Editing Tools.
Bandyopadhyay A; Mazumdar S; Yin X; Quick WP
Adv Exp Med Biol; 2017; 1016():101-120. PubMed ID: 29130156
[TBL] [Abstract][Full Text] [Related]
28. CRISPR technologies for precise epigenome editing.
Nakamura M; Gao Y; Dominguez AA; Qi LS
Nat Cell Biol; 2021 Jan; 23(1):11-22. PubMed ID: 33420494
[TBL] [Abstract][Full Text] [Related]
29. Epigenome editing in cancer: Advances and challenges for potential therapeutic options.
Lee SW; Frankston CM; Kim J
Int Rev Cell Mol Biol; 2024; 383():191-230. PubMed ID: 38359969
[TBL] [Abstract][Full Text] [Related]
30. Gene editing tools: state-of-the-art and the road ahead for the model and non-model fishes.
Barman HK; Rasal KD; Chakrapani V; Ninawe AS; Vengayil DT; Asrafuzzaman S; Sundaray JK; Jayasankar P
Transgenic Res; 2017 Oct; 26(5):577-589. PubMed ID: 28681201
[TBL] [Abstract][Full Text] [Related]
31. Cancer induction and suppression with transcriptional control and epigenome editing technologies.
Nakade S; Yamamoto T; Sakuma T
J Hum Genet; 2018 Feb; 63(2):187-194. PubMed ID: 29215091
[TBL] [Abstract][Full Text] [Related]
32. [Current advances and future prospects of genome editing technology in the field of biomedicine.].
Sakuma T
Clin Calcium; 2017; 27(12):1788-1793. PubMed ID: 29179174
[TBL] [Abstract][Full Text] [Related]
33. Recent Progress in Genome Editing Approaches for Inherited Cardiovascular Diseases.
Kaur B; Perea-Gil I; Karakikes I
Curr Cardiol Rep; 2018 Jun; 20(7):58. PubMed ID: 29860642
[TBL] [Abstract][Full Text] [Related]
34. Allele-Specific Epigenome Editing.
Bashtrykov P; Jeltsch A
Methods Mol Biol; 2018; 1767():137-146. PubMed ID: 29524132
[TBL] [Abstract][Full Text] [Related]
35. [Research Progress on Application of CRISPR/Cas Genome Editing Technology in Hematological Diseases -Review].
Xin LY; Liu AF; Zhong SS; Chen YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1284-8. PubMed ID: 27531817
[TBL] [Abstract][Full Text] [Related]
36. Current therapies for osteoarthritis and prospects of CRISPR-based genome, epigenome, and RNA editing in osteoarthritis treatment.
Chen Y; Luo X; Kang R; Cui K; Ou J; Zhang X; Liang P
J Genet Genomics; 2024 Feb; 51(2):159-183. PubMed ID: 37516348
[TBL] [Abstract][Full Text] [Related]
37. Toward the Development of Epigenome Editing-Based Therapeutics: Potentials and Challenges.
Ueda J; Yamazaki T; Funakoshi H
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902207
[TBL] [Abstract][Full Text] [Related]
38. Developmental history and application of CRISPR in human disease.
Liang P; Zhang X; Chen Y; Huang J
J Gene Med; 2017 Jun; 19(6-7):. PubMed ID: 28623876
[TBL] [Abstract][Full Text] [Related]
39. Applications of genome editing by programmable nucleases to the metabolic engineering of secondary metabolites.
Leitão AL; Costa MC; Enguita FJ
J Biotechnol; 2017 Jan; 241():50-60. PubMed ID: 27845165
[TBL] [Abstract][Full Text] [Related]
40. From Reductionism to Holism: Toward a More Complete View of Development Through Genome Engineering.
Delker RK; Mann RS
Adv Exp Med Biol; 2017; 1016():45-74. PubMed ID: 29130153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
